• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Unconventional myosin-Vc (MYO5C), Truncated

ACP11469

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP11469 Target NameMYO5C
Target SynonymsMGC74969; MYO5C; MYO5C_HUMAN; Myosin 5C; myosin VC; Unconventional myosin-VcFormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Protein LengthPartial
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ9NQX4
Background Information
  • Uniprot Id

    Q9NQX4

  • Target Species

    Human

  • Target Name

    MYO5C

  • Target Full Name

    Unconventional myosin-Vc

  • Target Function

    May be involved in transferrin trafficking. Likely to power actin-based membrane trafficking in many physiologically crucial tissues.

  • Target Protein Families

    TRAFAC class myosin-kinesin ATPase superfamily, Myosin family

  • Target Tissue Specificity

    Expressed chiefly in non-neuronal tissues. Particularly abundant in epithelial and glandular tissues including pancreas, prostate, mammary, stomach, colon and lung.

  • Target Synonyms

    MGC74969; MYO5C; MYO5C_HUMAN; Myosin 5C; myosin VC; Unconventional myosin-Vc

  • Target Background

    Predicted to enable actin filament binding activity and microfilament motor activity. Predicted to be involved in actin filament organization and vesicle transport along actin filament. Located in extracellular exosome.

Inquire Recombinant Human Unconventional myosin-Vc (MYO5C), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification